

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A method of delivering one or more immune response modifier (IRM) compounds to a tissue in a subject, the method comprising administering an IRM preparation to the subject, wherein the IRM preparation comprises a soluble IRM-polymer complex comprising one or more IRM compounds covalently attached to a polymer,
wherein the IRM compound is selected from the group consisting of imidazoquinoline amines; tetrahydroimidazoquinoline amines; and imidazopyridine amines; 1,2-bridged imidazoquinoline amines; 6,7-fused cycloalkylimidazopyridine amines; imidazonaphthyridine amines; tetrahydroimidazonaphthyridine amines; oxazoloquinoline amines; thiazoloquinoline amines; oxazolopyridine amines; thiazolopyridine amines; oxazonaphthyridine amines; thiazolonaphthyridine amines; 1H-imidazo dimers fused to pyridine amines, quinoline amines, tetrahydroquinoline amines, naphthyridine amines, or tetrahydronaphthyridine amines; and combinations thereof, and
wherein the polymer is a soluble polymer selected from the group consisting of poly(alkylene glycols), poly(olefinic alcohols), polyvinylpyrrolidones, poly(hydroxyalkylmethacrylamides), poly(hydroxyalkylmethacrylates), polyvinyl alcohols, polyoxazolines, poly(acrylic acids), polyacrylamides, polyglutamates, polylysines, polysaccharides, and combinations thereof.
2. (Original) A method of delivering one or more IRM compounds to a tissue in a subject, the method comprising administering an IRM preparation to the subject, wherein the IRM preparation comprises a soluble IRM-polymer complex comprising one or more IRM compounds attached to a soluble polymer comprising alkylene oxide moieties, wherein the IRM-polymer complex has a molecular weight of 1 kDa to 500 kDa.
3. (Canceled)

4. (Previously presented) The method of claim 1 wherein the soluble IRM-polymer complex has a solubility of at least 0.1 microgram per milliliter in water under physiological conditions.

5.-13. (Canceled)

14. (Previously presented) The method of claim 1 wherein the tissue is a tumor.

15. (Previously presented) The method of claim 14 wherein the tumor is a breast cancer tumor, a stomach cancer tumor, a lung cancer tumor, a head or neck cancer tumor, a colorectal cancer tumor, a renal cell carcinoma tumor, a pancreatic cancer tumor, a basal cell carcinoma tumor, a cervical cancer tumor, a melanoma cancer tumor, a prostate cancer tumor, an ovarian cancer tumor, or a bladder cancer tumor.

16-17. (Canceled)

18. (Currently amended) The method of claim 1 wherein the IRM is an agonist of at least one toll-like receptor (TLR) selected from the group consisting of TLR7 and TLR8.

19.-52. (Canceled)